Joey Orpilla

TL;DR: It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.

TL;DR: These studies elucidate the role that TIMs play in mediating adaptive immune resistance in the GBM microenvironment and provide evidence that they can be manipulated pharmacologically with agents that are clinically available.

TL;DR: Findings strongly suggest that the PD-1/PD-L1 pathway plays an important role in the adaptive immune resistance of established GBM in response to antitumor active vaccination and provide a rationale for the clinical translation of this combination therapy.

TL;DR: A novel noninvasive imaging combination that could distinguish intracranial immune responses from tumor progression in mice bearing orthotopic gliomas and in patients with glioblastomas is identified.

TL;DR: Interferon-mediated changes in the myeloid population were consistently observed following PD-1 blockade; these also mediated an increase in chemotactic factors that recruit T cells, however, sustained high expression of T-cell-suppressive checkpoints in these myeloids cells continued to prevent the optimal activation of the tumor infiltrating T cells.